Searching for 'the Goldilocks zone' – how a biotech VC firm translates difficult decisions into marketable medicines

Members of the deals team at Arix Bioscience (LSE: ARIX), a London-listed venture capital (VC) firm specializing in biotech, are so well-connected that they will never lack for new innovations to invest in.

But great science doesn’t always translate into commercial opportunities.

And anyone who looks closely will see that bringing the two together is far from easy – the high failure rates at all stages of drug development and the billions that the world’s biggest drug companies lose as a result, the consistent failure of generalist investors to succeed in biotech, and the team’s own academic and real-life experience of science and business are all evidence that this is a highly specialist field.